MESOBLAST LTD
MEOBFDrugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Prochymal®
Graft Versus Host Disease
Remestemcel-L
Grade B Acute Graft Versus Host Disease
Mesenchymal Precursor Cells (MPCs)
Heart Failure
NeoFuse
Degenerative Disc Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Prochymal® | Phase 3 | Graft Versus Host Disease | - | - |
Remestemcel-L | Phase 3 | Grade B Acute Graft Versus Host Disease | - | - |
Mesenchymal Precursor Cells (MPCs) | Phase 2 | Heart Failure | - | - |
NeoFuse | Phase 2 | Degenerative Disc Disease | - | - |
Frequently asked questions
What is in MESOBLAST LTD's drug pipeline?→
CatalystAlert tracks 4 drug candidates in MESOBLAST LTD's (MEOBF) pipeline across Phase 3, Phase 2. Its lead program is Prochymal® (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MESOBLAST LTD's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for MESOBLAST LTD (MEOBF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MEOBF biotech catalysts?→
Add MEOBF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MESOBLAST LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.